The Development of a New Class of Plasmodium falciparum M1 and M17 Inhibitors as Potential Antimalarials

Nearly half of the world’s population are at the risk of developing malaria, with children under the age of 5 being the most vulnerable group affected. The emergence of drug resistance is making most current malaria treatments ineffective, making this disease a global health priority. This medicinal chemistry research involved the design and synthesis of new molecules with desirable properties and efficacy. Throughout the PhD, newly made molecules were assessed for drug-like properties and activity against malaria parasites; permitting the identification of new leads with potent activity against drug-sensitive and drug-resistant parasites and improved drug-like properties.